3 results
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
The primary objective of the study is to determine feasibility of CEA assessments at home using (automated) capillary sampling. Home based (automated) capillary sampling will be considered feasible if a success rate of 85% or greater has been…
To determine whether dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of kidney failure, hospitalization for heart failure, and all-cause mortality in the overall patient group, consisting of patients…